TECREAL STUDY: TECLISTAMAB OUTCOMES IN THE CONTEXT OF REAL-WORLD TREATMENT PATTERNS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
Author(s)
Ana Jorge, MD1, Catarina Pestana Silva, MSc2, Eliana Aguiar, MD3, Eliana Martins, PharmD4, Helena Martins, MD5, Joana Oliveira Fagundes, PharmD4, Maria Inês Teodoro, PharmD6, Patrícia Ferraz, MD7, Susana Ferreira Santos, PharmD4, Teresa Ribeiro, MD8.
1Unidade Local de Saúde Lisboa Ocidental (ULSLO), Lisboa, Portugal, 2HE&OR Senior Researcher, Instituto de Saúde Baseada na Evidência (ISBE), Lisboa, Portugal, 3Centro Hospitalar Universitário São João (ULS São João), Porto, Portugal, 4Johnson & Johnson Innovative Medicine, Porto Salvo, Portugal, 5Hospital de Santa Maria (ULSSM), Lisbon, Portugal, 6Institute for Evidence-Based Health (ISBE), Lisboa, Portugal, 7Centro Hospitalar de Trás-Os-Montes e Alto Douro (ULSTMAD), Vila Real, Portugal, 8Hospital de Braga (ULSB), Braga, Portugal.
1Unidade Local de Saúde Lisboa Ocidental (ULSLO), Lisboa, Portugal, 2HE&OR Senior Researcher, Instituto de Saúde Baseada na Evidência (ISBE), Lisboa, Portugal, 3Centro Hospitalar Universitário São João (ULS São João), Porto, Portugal, 4Johnson & Johnson Innovative Medicine, Porto Salvo, Portugal, 5Hospital de Santa Maria (ULSSM), Lisbon, Portugal, 6Institute for Evidence-Based Health (ISBE), Lisboa, Portugal, 7Centro Hospitalar de Trás-Os-Montes e Alto Douro (ULSTMAD), Vila Real, Portugal, 8Hospital de Braga (ULSB), Braga, Portugal.
OBJECTIVES: Treatment options for relapsed/refractory multiple myeloma (RRMM) expanded rapidly in recent years. In addition to clinical trials, real-world studies provide important evidence on use and effectiveness of innovative therapies in routine clinical practice. This study aimed to evaluate efficacy of teclistamab in clinical trials (Tec-CT) and real-world evidence studies (Tec-RWE), as well as outcomes with real-world traditional standard-of-care regimens (SoC-RWE) in RRMM patients that received at least three prior therapies, including immunomodulatory agent, proteasome inhibitor, and anti-CD38 antibody.
METHODS: A targeted literature review was conducted using PubMed/MEDLINE and Cochrane Library to identify studies published 2019-2025. Primary analysis included Tec-CT, Tec-RWE and SoC-RWE studies in adults with triple-class exposed/refractory MM, ≥3 prior LoT, with no prior anti-BCMA therapy. Outcomes were summarized for overall response rate (ORR), ≥complete response (≥CR), ≥very good partial response (≥VGPR), duration of response (DoR), progression-free survival (PFS) and overall survival (OS) at month-6 and year-1.
RESULTS: Thirthy-two studies (n=3,670 patients) were included in the analysis (3 Tec-CT, 15 Tec-RWE, 14 SoC-RWE). Across studies, patients were heavily pretreated, with a median of 4-8 prior lines of therapy (range: 3-16). Efficacy outcomes for Tec-RWE varied between: ORR 44.0%-100.0%, ≥CR 20.0-69.0%, ≥VGPR 28.6%-57.1%, DoR year-1 55.0%-78.0%, PFS year-1 53.4%-75.0%, OS year-1 61.7%-91.5%. For Tec-CT outcomes varied between: ORR 63.0%-76.9%, ≥CR 46.1-65.4%, ≥VGPR 59.4%-76.9%, DoR year-1 71.0%-90.0%, PFS year-1 48.0%-77.0%, OS year-1 64.0%-83.5%. For SoC-RWE the efficacy outcomes ranged: ORR 25.0%-55.0%, ≥CR 0.0%-4.0%, ≥VGPR 0.71-36.0%, DoR year-1 7.0%-45.0%, PFS year-1 5.0%-25.0%, OS year-1 18.0%-55.0%.
CONCLUSIONS: These findings suggest that the clinical benefit of teclistamab observed in clinical trials is reproducible in broader real-world populations, despite potential differences in baseline characteristics, follow-up and treatment patterns. These results support the role of teclistamab as an effective treatment option in triple class exposed RRMM patients.
METHODS: A targeted literature review was conducted using PubMed/MEDLINE and Cochrane Library to identify studies published 2019-2025. Primary analysis included Tec-CT, Tec-RWE and SoC-RWE studies in adults with triple-class exposed/refractory MM, ≥3 prior LoT, with no prior anti-BCMA therapy. Outcomes were summarized for overall response rate (ORR), ≥complete response (≥CR), ≥very good partial response (≥VGPR), duration of response (DoR), progression-free survival (PFS) and overall survival (OS) at month-6 and year-1.
RESULTS: Thirthy-two studies (n=3,670 patients) were included in the analysis (3 Tec-CT, 15 Tec-RWE, 14 SoC-RWE). Across studies, patients were heavily pretreated, with a median of 4-8 prior lines of therapy (range: 3-16). Efficacy outcomes for Tec-RWE varied between: ORR 44.0%-100.0%, ≥CR 20.0-69.0%, ≥VGPR 28.6%-57.1%, DoR year-1 55.0%-78.0%, PFS year-1 53.4%-75.0%, OS year-1 61.7%-91.5%. For Tec-CT outcomes varied between: ORR 63.0%-76.9%, ≥CR 46.1-65.4%, ≥VGPR 59.4%-76.9%, DoR year-1 71.0%-90.0%, PFS year-1 48.0%-77.0%, OS year-1 64.0%-83.5%. For SoC-RWE the efficacy outcomes ranged: ORR 25.0%-55.0%, ≥CR 0.0%-4.0%, ≥VGPR 0.71-36.0%, DoR year-1 7.0%-45.0%, PFS year-1 5.0%-25.0%, OS year-1 18.0%-55.0%.
CONCLUSIONS: These findings suggest that the clinical benefit of teclistamab observed in clinical trials is reproducible in broader real-world populations, despite potential differences in baseline characteristics, follow-up and treatment patterns. These results support the role of teclistamab as an effective treatment option in triple class exposed RRMM patients.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
CO75
Topic
Clinical Outcomes, Health Service Delivery & Process of Care
Topic Subcategory
Clinical Outcomes Assessment, Comparative Effectiveness or Efficacy
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Oncology